Suppr超能文献

全球丙型肝炎疾病负担趋势:消除策略。

Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination.

机构信息

Swiss Hepatitis, Zurich, Switzerland.

Arud Centre for Addiction Medicine, Zurich, Switzerland.

出版信息

J Prev Med Public Health. 2021 Jul;54(4):251-258. doi: 10.3961/jpmph.21.151. Epub 2021 Jun 24.

Abstract

Hepatitis C infection is responsible for high morbidity and mortality rates globally as well as for significant indirect costs. The disease burden caused by the hepatitis C virus (HCV) is comparable to the one caused by human immunodeficiency virus or tuberculosis. Today, simple detection methods, highly effective and easy to administer therapies and efficient preventative measures are available to combat hepatitis C. Nevertheless, in most countries around the world, the World Health Organization target of eliminating this infectious disease and its consequences by 2030 are not being met. Significant gaps in care for hepatitis C sufferers still exist, the shortcomings ranging from education and treatment to aftercare. Hepatitis C infection was and still is not on the radar of most politicians and health authorities. National programmes and strategies to combat the disease exist or are being developed in many countries. However, for these to be implemented efficiently and successfully, clear political commitment, strong civil society actors, well-functioning public health structures and the relevant support from global donors are needed.

摘要

丙型肝炎感染在全球范围内导致高发病率和死亡率,并造成重大间接成本。丙型肝炎病毒(HCV)造成的疾病负担可与人类免疫缺陷病毒或结核病造成的负担相媲美。如今,已有简单的检测方法、高效且易于管理的治疗方法和有效的预防措施可用于对抗丙型肝炎。然而,在世界上大多数国家,世界卫生组织到 2030 年消除这一传染病及其后果的目标并未实现。丙型肝炎患者的护理仍存在显著差距,从教育和治疗到后续护理都存在不足。丙型肝炎感染过去没有、现在也没有引起大多数政治家和卫生当局的关注。许多国家都制定了国家方案和战略来防治这种疾病。然而,要想有效和成功地实施这些方案和战略,就需要明确的政治承诺、强有力的民间社会行为体、运作良好的公共卫生结构以及全球捐助者的相关支持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e8/8357539/c784b97923d2/jpmph-21-151f1.jpg

相似文献

1
Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination.
J Prev Med Public Health. 2021 Jul;54(4):251-258. doi: 10.3961/jpmph.21.151. Epub 2021 Jun 24.
3
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184. doi: 10.1016/S2468-1253(18)30270-X.
4
NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements. 2002;19(3):1-46.
7
Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings.
Semin Liver Dis. 2012 May;32(2):147-57. doi: 10.1055/s-0032-1316476. Epub 2012 Jul 3.
8
A model of the economic benefits of global hepatitis C elimination: an investment case.
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):940-947. doi: 10.1016/S2468-1253(20)30008-X. Epub 2020 Jul 27.
9
How to set the agenda for hepatitis C: a theory-driven policy analysis.
Health Res Policy Syst. 2022 Feb 14;20(1):20. doi: 10.1186/s12961-022-00824-3.
10
Micro-elimination of hepatitis C virus.
Liver Int. 2020 Feb;40 Suppl 1:67-71. doi: 10.1111/liv.14363.

引用本文的文献

1
Why patients' knowledge alone isn't enough: examining behavioral and attitudinal gaps in gestational diabetes management among Chinese women.
Front Public Health. 2025 Aug 21;13:1589416. doi: 10.3389/fpubh.2025.1589416. eCollection 2025.
2
Beyond boundaries: Redefining the donor frontier in pediatric lung transplantation.
JHLT Open. 2025 Jul 25;10:100355. doi: 10.1016/j.jhlto.2025.100355. eCollection 2025 Nov.
6
The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021.
Liver Int. 2025 Mar;45(3):e70001. doi: 10.1111/liv.70001.
7
8
Reduced injection risk behavior with co-located hepatitis C treatment at a syringe service program: The accessible care model.
PLoS One. 2024 Aug 29;19(8):e0308102. doi: 10.1371/journal.pone.0308102. eCollection 2024.
9
Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.
Microorganisms. 2024 May 21;12(6):1035. doi: 10.3390/microorganisms12061035.
10
Advancing Hepatitis C Elimination in Africa: Insights from Egypt.
Hepat Med. 2024 Jun 4;16:37-44. doi: 10.2147/HMER.S470344. eCollection 2024.

本文引用的文献

2
Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals.
J Viral Hepat. 2021 Jan;28(1):142-146. doi: 10.1111/jvh.13398. Epub 2020 Sep 22.
3
Global hepatitis C elimination: an investment framework.
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):927-939. doi: 10.1016/S2468-1253(20)30010-8. Epub 2020 Jul 27.
4
A model of the economic benefits of global hepatitis C elimination: an investment case.
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):940-947. doi: 10.1016/S2468-1253(20)30008-X. Epub 2020 Jul 27.
5
Ukrainian health authorities adopt hepatitis C project.
Lancet. 2020 Jul 25;396(10246):228. doi: 10.1016/S0140-6736(20)31639-1.
6
7
Global timing of hepatitis C virus elimination in high-income countries.
Liver Int. 2020 Mar;40(3):522-529. doi: 10.1111/liv.14324. Epub 2019 Dec 23.
9
Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study.
Lancet Gastroenterol Hepatol. 2019 Oct;4(10):794-804. doi: 10.1016/S2468-1253(19)30227-4. Epub 2019 Jul 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验